Latest news with #Hauppauge
Globe and Mail
01-08-2025
- Business
- Globe and Mail
Cemtrex Issues Shareholder Update Highlighting Growth Across Vicon and AIS Divisions, Strategic Initiatives in Blockchain and Automation
Hauppauge, NY, Aug. 01, 2025 (GLOBE NEWSWIRE) -- – Cemtrex Inc. (Nasdaq: CETX), a technology company focused on intelligent security and industrial services, today issued a shareholder update from Chairman and CEO Saagar Govil outlining the Company's progress across its core divisions and strategic roadmap for long-term growth: To our shareholders, Cemtrex today is stronger, sharper, and more focused than at any point in the last several years. We've been building deliberately investing in the right products, winning critical contracts, and executing a strategy that positions us to lead where the world is heading. Vicon: Momentum, Execution, and the Launch of NEXT Vicon, our intelligent security division, is performing. Since 2021, we've grown revenue from $21 million to a projected $36 million-plus for fiscal year 2025. Gross margins have improved, and our go-to-market engine is accelerating, fueled by the addition of over 60 new resellers this year alone. Our new modular camera platform, NEXT, began shipping this quarter. It's our most advanced product line to date—fast to install, AI-powered, visually modern, and designed to meet the complex needs of today's enterprise and public infrastructure buyers. Early wins, including a $500K school district deployment, are encouraging. We believe this platform has the potential to become the core of Vicon's next growth phase. This year, Vicon has delivered: $1.2M U.S. county security project $1.2M U.S. border security contract $1M international deployment in Saudi Arabia $800K system for a UK prison facility $10.4M contract in December 2024—the largest in our history These are not pipeline projections—they're closed deals. Vicon is performing in the market, and we are scaling it with intention. AIS: Durable Growth with Strategic Ambition AIS has quietly doubled in size since 2021, with revenue on track to exceed $36 million this year. Demand from food and beverage, packaging, and machinery sectors remains strong, and reshoring trends are creating more opportunity for our services. We are no longer just a millwright and installation business. We are positioning AIS to become a full-spectrum industrial services platform, one that can handle legacy systems and lead the transition to automated, robotics-enabled manufacturing environments. To that end, we are in advanced discussions to acquire a Midwest-based robotics integrator. This deal, if completed, would expand our capabilities into robotic workcell design, controls programming, and systems integration, allowing us to better serve manufacturers modernizing their facilities. Our M&A playbook is disciplined. Our last acquisition was accretive, smoothly integrated, and strengthened our platform. We expect the same results as we scale. Solana and Blockchain Infrastructure In July, we allocated $1 million into Solana (SOL) and have since staked our holdings. We view Solana as one of the most structurally sound blockchains in production—high throughput, low latency, and deflationary mechanics hardcoded into the protocol. This is not a hedge. It's a strategic bet. Blockchain infrastructure will become critical to how digital systems establish truth. Whether it's timestamping surveillance footage, detecting tampering in AI-generated content, or anchoring public safety evidence in immutable ledgers—we believe this technology will be foundational. Vicon has already begun R&D around blockchain-based video authentication. We intend to move quickly. Forward Strategy We have doubled the business over the last four years. Now, we intend to double again. Our roadmap to $150 million in revenue and $15 million in operating income is built on real contracts, real expansion, and real infrastructure. We're executing bolt-on M&A with discipline, pushing into automation and digital trust, and operating two divisions—Vicon and AIS—that are both scaling in the right direction. We're also evaluating opportunities to expand beyond our current two operating segments. As adjacent markets evolve and strategic opportunities emerge, we remain open to adding a third leg to the Cemtrex platform—one that aligns with our operating philosophy and long-term growth thesis. The stock doesn't yet reflect the business we've built. That's not our focus. Our job is to keep growing revenue, expanding margins, and building a platform that's so compelling it's impossible to ignore. Thank you for your continued support, Saagar Govil Chairman & CEO Cemtrex, Inc. About Cemtrex Cemtrex, Inc. (Nasdaq: CETX) is a diversified technology company operating in the Security and Industrial sectors. Its Security segment, led by Vicon Industries, provides advanced video management software, high-performance security cameras, and integrated surveillance solutions for enterprise, government, and critical infrastructure. The Industrial segment, through Advanced Industrial Services (AIS), delivers expert rigging, millwrighting, process piping, and equipment installation services to manufacturers nationwide. With a focus on innovation, execution, and strategic growth, Cemtrex is committed to enhancing safety, efficiency, and value for its customers and shareholders. For more information, visit Investor Relations: investors@ Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the closing of the offering, gross proceeds from the offering, our new product offerings, expected use of proceeds, or any proposed fundraising activities. These forward-looking statements are based on management's current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those set forth in or implied by such forward looking statements. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. These risks and uncertainties are discussed under the heading 'Risk Factors' contained in our Form 10-K filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release and we undertake no duty to update this information unless required by law.
Yahoo
24-06-2025
- Sport
- Yahoo
Will the Islanders bring James Hagens home? GM Mathieu Darche weighs his options in the NHL draft
FILE - Boston College forward James Hagens (10) reacts after scoring a goal during the third period of an NCAA hockey regionals game against Bentley on March 28, 2025, in Manchester, N.H. (AP Photo/Greg M. Cooper, file) FILE - Boston College forward James Hagens (10) reacts after scoring a goal during the third period of an NCAA hockey regionals game against Bentley on March 28, 2025, in Manchester, N.H. (AP Photo/Greg M. Cooper, file) Mathieu Darche's phone keeps ringing as he prepares for his first NHL draft as general manager of the New York Islanders, and he's sure of only one thing: They are not trading the No. 1 pick. Beyond that, it's wide open. While Darche is not saying, the growing consensus is the Islanders are expected to select defenseman Matthew Schaefer on Friday night. Advertisement With Long Island native James Hagens also in the mix as a likely top-10 pick, there has been plenty of speculation about them making a splash to trade back into the first half of the first round to get both. 'I'm looking at everything," Darche said on a video call with reporters Tuesday. "If I feel the opportunity warrants that trade, I'll try it. ... Whether it's moving up in the draft with another pick, whether it's acquiring another pick, whether it's trading another pick to get a player, I'm looking at all options to improve our team.' Hagens grew up in Hauppauge going to Nassau Coliseum as a kid. He still has the towel from his first playoff game, and his buddies who are Islanders fans were pumped to see them win the draft lottery to get the first pick. It has started to look increasingly unlikely that Hagens is the top prospect in this draft, but that has not stopped folks in the New York area from rooting for Darche to keep the local boy. Hagens has had people approach him on the golf course and recently saw a bumper sticker reading, 'Bring Hagens Home,' at which point he tried to drive by without making eye contact. Advertisement 'It was cool,' Hagens a bit blushingly acknowledged. 'Moments like that, it puts a smile on your face.' Hagens, a 5-foot-11 center who was a point-a-game player during his freshman season at Boston College, spoke with Darche but also sounds at peace with the possibility he ends up somewhere else. "I have no idea what's going to happen on draft day, so it's just being ready," Hagens said during the top prospects' visit to the Stanley Cup Final in South Florida earlier this month. 'I know that whatever team does takes the chance on me, I'm a loyal guy so I'd want to stick with them for however long they want me. I just want to be at a spot that wants me the most." That still could be the Islanders, though probably not the rival Rangers after they transferred the 12th pick to Pittsburgh on Tuesday to complete an earlier trade and keep their first-rounder next year. Maybe Hagens is playing down I-95 in Philadelphia, up the East Coast in Boston or across New York in Buffalo. Advertisement Schaefer and a couple of centers, Canadian Michael Misa and Swede Anton Frondell, are expected to be the top three off the board. San Jose, which took Macklin Celebrini first a year ago, and Chicago, which got Connor Bedard at No. 1 in 2023, have the second and third picks after New York. "We're going to keep debating it till the end, keep calling around and getting as much info," said Darche, who spent seven seasons in Tampa Bay's front office before getting his first job running an NHL team. 'There's a few guys we like, and do I have an idea at this point because it's in four days? Probably. But we're going to keep doing our due diligence all the way through Friday.' Asked specifically about Schaefer, Darche raved about the maturity of the soon-to-be-18-year-old, who has dealt with the grief of the deaths of his mom and his junior hockey host family mother in Erie and has turned it into a way of helping others. 'He's an impressive young man,' Darche said. "He's a hell of a player. He's a great person. But having said that, there's a lot of other kids at the draft that we met that are very impressive. That's why I say, regardless of who we pick on Friday, we'll get a special player that's going to help the New York Islanders fairly quickly.' ___ AP NHL:
Yahoo
18-06-2025
- Health
- Yahoo
Saptalis Pharmaceuticals Launches Fluoxetine Oral Solution, USP 20 mg/5 mL
HAUPPAUGE, N.Y., June 18, 2025--(BUSINESS WIRE)--Saptalis Pharmaceuticals, LLC. is pleased to announce the commercial launch of Fluoxetine Oral Solution, USP 20 mg/5 mL, a prescription-only selective serotonin reuptake inhibitor (SSRI) developed to treat a range of mental health conditions effectively. This oral formulation is designed to support flexible and individualized treatment, particularly for patients who experience difficulty swallowing solid dosage forms. Fluoxetine Oral Solution is indicated for the following conditions: Acute and maintenance treatment of Major Depressive Disorder (MDD) Acute and maintenance treatment of Obsessive-Compulsive Disorder (OCD) Acute and maintenance treatment of Bulimia Nervosa Acute treatment of Panic Disorder, with or without agoraphobia "We are excited to expand our product portfolio with the introduction of Fluoxetine Oral Solution," said Polireddy Dondeti, Ph.D., President and CEO, of Saptalis Pharmaceuticals, LLC. "This launch reflects our ongoing commitment to providing high-quality, accessible medications that meet the evolving needs of both patients and healthcare professionals." Fluoxetine Oral Solution, USP 20 mg/5 mL is available by prescription and should only be used under the guidance of a licensed healthcare provider to ensure safe and effective treatment. For full prescribing information or to learn more, please visit or contact us at info@ About Saptalis Pharmaceuticals, LLC. Saptalis Pharmaceuticals, LLC. is a rapidly growing company focused on the development, manufacturing, and commercialization of specialty pharmaceutical products, including complex and high-quality generics, with particular expertise in liquid and semi-solid dosage forms. Headquartered in Hauppauge, New York, Saptalis operates fully equipped R&D laboratories and a state-of-the-art commercial manufacturing facility compliant with U.S. FDA cGMP standards. The company is dedicated to delivering innovative solutions that enhance patient care and improve treatment outcomes. View source version on Contacts Peruvemba SatishChief Financial Officer & Chief Commercial Officer(631) 231 2751 x211info@
Yahoo
18-06-2025
- Health
- Yahoo
Saptalis Pharmaceuticals Launches Fluoxetine Oral Solution, USP 20 mg/5 mL
HAUPPAUGE, N.Y., June 18, 2025--(BUSINESS WIRE)--Saptalis Pharmaceuticals, LLC. is pleased to announce the commercial launch of Fluoxetine Oral Solution, USP 20 mg/5 mL, a prescription-only selective serotonin reuptake inhibitor (SSRI) developed to treat a range of mental health conditions effectively. This oral formulation is designed to support flexible and individualized treatment, particularly for patients who experience difficulty swallowing solid dosage forms. Fluoxetine Oral Solution is indicated for the following conditions: Acute and maintenance treatment of Major Depressive Disorder (MDD) Acute and maintenance treatment of Obsessive-Compulsive Disorder (OCD) Acute and maintenance treatment of Bulimia Nervosa Acute treatment of Panic Disorder, with or without agoraphobia "We are excited to expand our product portfolio with the introduction of Fluoxetine Oral Solution," said Polireddy Dondeti, Ph.D., President and CEO, of Saptalis Pharmaceuticals, LLC. "This launch reflects our ongoing commitment to providing high-quality, accessible medications that meet the evolving needs of both patients and healthcare professionals." Fluoxetine Oral Solution, USP 20 mg/5 mL is available by prescription and should only be used under the guidance of a licensed healthcare provider to ensure safe and effective treatment. For full prescribing information or to learn more, please visit or contact us at info@ About Saptalis Pharmaceuticals, LLC. Saptalis Pharmaceuticals, LLC. is a rapidly growing company focused on the development, manufacturing, and commercialization of specialty pharmaceutical products, including complex and high-quality generics, with particular expertise in liquid and semi-solid dosage forms. Headquartered in Hauppauge, New York, Saptalis operates fully equipped R&D laboratories and a state-of-the-art commercial manufacturing facility compliant with U.S. FDA cGMP standards. The company is dedicated to delivering innovative solutions that enhance patient care and improve treatment outcomes. View source version on Contacts Peruvemba SatishChief Financial Officer & Chief Commercial Officer(631) 231 2751 x211info@ Error al recuperar los datos Inicia sesión para acceder a tu cartera de valores Error al recuperar los datos Error al recuperar los datos Error al recuperar los datos Error al recuperar los datos
Globe and Mail
16-06-2025
- Business
- Globe and Mail
Dime Continues to Execute on Growth Plan with the Hire of Shawn Gines
HAUPPAUGE, N.Y., June 16, 2025 (GLOBE NEWSWIRE) -- As part of the continued execution of its growth plan, Dime Community Bancshares, Inc. (NASDAQ: DCOM) (the 'Company' or 'Dime'), the parent company of Dime Community Bank (the 'Bank'), announced today that Shawn Gines will join Dime as Executive Vice President, Corporate and Specialty Finance. Mr. Gines will play an integral role in the continued buildout and diversification of Dime's commercial lending businesses, including growing Dime's presence with corporate clients and private equity firms, overseeing the recently launched Fund Finance vertical, and building out other specialty verticals which over time will further diversify Dime's balance sheet. Stuart H. Lubow, President and Chief Executive Officer of Dime, said, "We are excited to announce the hiring of Shawn, who will be one of the cornerstones of our growth plans in the years ahead. Shawn is a very well-known and well-regarded banker with a strong track record. Dime continues to be the bank of choice for talented bankers.' 'Shawn's diverse experience in the geographies and asset classes we're building out will significantly accelerate our execution,' said Tom Geisel, Dime's Senior Executive Vice President of Commercial Lending. Gines, who will be based in Manhattan, was most recently Regional President for the NYC and New Jersey Metro Markets for Webster Bank. Previously, he was Senior Managing Director and led a Middle Market Commercial group at Sterling National Bank. Early in his career, Mr. Gines was employed at GE Capital and Bank of America where he held various roles with increasing responsibility. ABOUT DIME COMMUNITY BANCSHARES, INC. Dime Community Bancshares, Inc. is the holding company for Dime Community Bank, a New York State-chartered trust company with over $14 billion in assets and the number one deposit market share among community banks on Greater Long Island (1). ¹ Aggregate deposit market share for Kings, Queens, Nassau & Suffolk counties for community banks with less than $20 billion in assets.
